ExpertThis question is part of a case study — click to read the full scenario(Case 21)
Section B - Case 2: BioGenix
Scenario: BioGenix is a biotechnology firm developing a new gene therapy, 'GeneX'. During the year ended 31 December 20X5, BioGenix incurred the following costs:
- $2,000,000 on the research phase (Jan-Jun).
- $3,000,000 on the development phase (Jul-Dec), incurred evenly over the 6 months.
BioGenix management confirmed that the project met all IAS 38 capitalization criteria on 1 October 20X5.
BioGenix also holds a patent for a different drug. On 1 January 20X5, BioGenix licensed this patent to PharmaCo. PharmaCo paid an upfront, non-refundable fee of $5,000,000 for the right to use the patent for 5 years. BioGenix has no further performance obligations. The contract also includes a $2,000,000 milestone payment if PharmaCo achieves $50m in sales in 20X5. By 31 December 20X5, PharmaCo's sales were $30m, and BioGenix determined it is highly probable the milestone will not be met.
Finally, BioGenix has a Cash Generating Unit (CGU) that was impairment tested. Carrying amounts: Goodwill $1m, Patent $4m, Equipment $5m. Recoverable amount of the CGU is $7m.
Question: How much of the 'GeneX' costs should be capitalized as an intangible asset for the year ended 31 December 20X5?
ACCA · Question 23 · Revenue from Contracts with Customers
Section B - Case 2: BioGenix
Scenario: BioGenix is a biotechnology firm developing a new gene therapy, 'GeneX'. During the year ended 31 December 20X5, BioGenix incurred the following costs:
- $2,000,000 on the research phase (Jan-Jun).
- $3,000,000 on the development phase (Jul-Dec), incurred evenly over the 6 months.
BioGenix management confirmed that the project met all IAS 38 capitalization criteria on 1 October 20X5.
BioGenix also holds a patent for a different drug. On 1 January 20X5, BioGenix licensed this patent to PharmaCo. PharmaCo paid an upfront, non-refundable fee of $5,000,000 for the right to use the patent for 5 years. BioGenix has no further performance obligations. The contract also includes a $2,000,000 milestone payment if PharmaCo achieves $50m in sales in 20X5. By 31 December 20X5, PharmaCo's sales were $30m, and BioGenix determined it is highly probable the milestone will not be met.
Finally, BioGenix has a Cash Generating Unit (CGU) that was impairment tested. Carrying amounts: Goodwill $1m, Patent $4m, Equipment $5m. Recoverable amount of the CGU is $7m.
Question: How much revenue should BioGenix recognize from the PharmaCo licensing agreement for the year ended 31 December 20X5?
Section B - Case 2: BioGenix
Scenario: BioGenix is a biotechnology firm developing a new gene therapy, 'GeneX'. During the year ended 31 December 20X5, BioGenix incurred the following costs:
- $2,000,000 on the research phase (Jan-Jun).
- $3,000,000 on the development phase (Jul-Dec), incurred evenly over the 6 months.
BioGenix management confirmed that the project met all IAS 38 capitalization criteria on 1 October 20X5.
BioGenix also holds a patent for a different drug. On 1 January 20X5, BioGenix licensed this patent to PharmaCo. PharmaCo paid an upfront, non-refundable fee of $5,000,000 for the right to use the patent for 5 years. BioGenix has no further performance obligations. The contract also includes a $2,000,000 milestone payment if PharmaCo achieves $50m in sales in 20X5. By 31 December 20X5, PharmaCo's sales were $30m, and BioGenix determined it is highly probable the milestone will not be met.
Finally, BioGenix has a Cash Generating Unit (CGU) that was impairment tested. Carrying amounts: Goodwill $1m, Patent $4m, Equipment $5m. Recoverable amount of the CGU is $7m.
Question: How much revenue should BioGenix recognize from the PharmaCo licensing agreement for the year ended 31 December 20X5?
Answer options:
$1,000,000
$5,000,000
$7,000,000
$1,400,000
How to approach this question
Full Answer
Common mistakes
Practice the full ACCA FR — Financial Reporting Practice Exam 4
32 questions · hints · full answers · grading